Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks
NASDAQ:PTIX

Atrinsic 8/14/2024 Earnings Report

Atrinsic logo
$2.75 -0.05 (-1.79%)
Closing price 08/12/2025 04:00 PM Eastern
Extended Trading
$2.74 -0.01 (-0.33%)
As of 08/12/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

Atrinsic EPS Results

Actual EPS
-$5.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Atrinsic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Atrinsic Announcement Details

Quarter
Date
8/14/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Atrinsic's next earnings date is estimated for Wednesday, August 13, 2025, based on past reporting schedules.

Conference Call Resources

Atrinsic Earnings Headlines

Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
July 30, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/30/3124067/0/en/protagenic-therapeutics-announces-grant-of-new-patent-in-japan-for-its-modified-stilbenoid-program-drug-candidates.html
Protagenic Therapeutics, Inc. (PTIX) - Yahoo Finance
June 24, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/PTIX/news/
REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).
 |  Weiss Ratings (Ad)
Protagenic & Phytanix Merge in All-Stock Move, Sparking Retail Frenzy
May 29, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/protagenic-phytanix-merge-in-all-stock-move-sparking-retail-frenzy/ar-AA1FJicU
Protagenic Therapeutics swaps warrants for shares
May 21, 2025  |  uk.investing.comhttps://uk.investing.com/news/sec-filings/protagenic-therapeutics-swaps-warrants-for-shares-93CH-4095880
Protagenic Therapeutics Shares Double After Buyout Offer From Phytanix Bio
May 20, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/protagenic-therapeutics-shares-double-after-buyout-offer-from-phytanix-bio-4ee93d1e
See More Atrinsic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atrinsic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atrinsic and other key companies, straight to your email.

About Atrinsic

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

View Atrinsic Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles